Ahngook Pharmaceuticals has presented the results of the domestic phase 3 clinical trials for Rupafin, a second-generation antihistamine that treats allergic diseases, at the 2017 Korean Academy of Asthma, Allergy and Clinical Immunology 대한천식알레르기학회 fall symposium.
|Professor Kim Dae-woo from the Department of Otorhinolaryngology at SMG-SMU Borame Medical Center presenting the domestic phase 3 clinical trials for Rupafin at the 2017 Korean Academy of Asthma, Allergy and Clinical Immunology fall symposium.|
“In addition to antihistaminic effects, Rupafin has a broader and more potent anti-inflammatory and strong allergic reaction inhibition effects than the other compounds,” said Professor Kim Dae-woo 김대우, one of the participants in the clinical trial from the Department of Otorhinolaryngology at SMG-SMU Borame Medical Center 보라매병원.
Such effects are due to the double action of inhibiting the platelet activating factor (PAF), which is known to be involved in various inflammatory reactions, Kim noted. “The 4NTSS (4 Nasal Total Symptom Score) for patients treated with Rupafin was also superior to the placebo group after 28 days,” he added.
The company 안국약품 plans to release the drug on Dec. 1. The release of the drug will mark the first new antihistamines treatment in Korea since the desloratadine was released six years ago.
<© Korea Biomedical Review, All rights reserved.>